Anti tumor necrosis factor - alpha adalimumab for complex regional pain syndrome type 1 (CRPS-I): A case series

Pain Practice

Volumn 13, Issue 8, 2013, Pages 649-656

  Eisenberg, Elon ^a,b,d   Sandler, Ifat ^b   Treister, Roi ^b,c   Suzan, Erica ^a   Haddad, May ^b,c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Institute of Pain Medicine   (Israel)

^c UNIVERSITY OF HAIFA   (Israel)

^d NONE   (Israel)

Author keywords

Adalimumab; Anti inflammatory agents; Complex regional pain syndromes; CRPS; Tissue necrosis factor; TNF

Indexed keywords

ADALIMUMAB;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; COMPLEX REGIONAL PAIN SYNDROME TYPE I; FEMALE; HUMAN; MALE; MCGILL PAIN QUESTIONNAIRE; PAIN THRESHOLD; SHORT FORM 36; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; COMPLEX REGIONAL PAIN SYNDROMES; CRPS; TISSUE NECROSIS FACTOR; TNF-Α;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PILOT PROJECTS; REFLEX SYMPATHETIC DYSTROPHY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84887406333     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12070     Document Type: Article

References (17)

1. Huygen FJ, De Bruijn AG, De Bruin MT, Groeneweg JG, Klein J, Zijlstra FJ. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. 2002;11:47-51.
2. Wesseldijk F, Huygen FJ, Heijmans-Antonissen C, Niehof SP, Zijlstra FJ. Six years follow-up of the levels of TNF-alpha and IL-6 in patients with complex regional pain syndrome type 1. Mediators Inflamm. 2008;2008:439-469.
3. Wesseldijk F, Huygen FJ, Heijmans-Antonissen C, Niehof SP, Zijlstra FJ. Tumor necrosis factor-alpha and interleukin-6 are not correlated with the characteristics of Complex Regional Pain Syndrome type 1 in 66 patients. Eur J Pain. 2008;12:716-721.
4. Krämer HH, Eberle T, Uçeyler N, et al. TNF-α in CRPS and 'normal' trauma-significant differences between tissue and serum. Pain. 2011;152:285-290.
5. Mainhofner C, Handwerker HO, Neundorfer B, Birklein F. Mechanical hyperalgesia in complex regional pain syndrome: a role for TNF-α. Neurology. 2005;65:311-313.
6. Dirckx M, Stronks DL, Groeneweg G, Huygen FJ. Effect of immunomodulating medications in complex regional pain syndrome: a systematic review. Clin J Pain. 2012;28:355-363.
7. Huygen FJ, Niehof S, Zijlstra FJ, van Hagen PM, van Daele PLA. Successful treatment of CRPS 1 with anti-TNF. J Pain Symptom Manage. 2004;27:101-103.
8. Bernateck M, Rolke R, Birklein F, Treede RD, Fink M, Karst M. Successful intravenous regional block with low-dose tumor necrosis factor-α antibody infliximab for treatment of regional pain syndrome 1. Anesth Analg 2007;105:1148-1151.
9. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002;61(Suppl 2):ii70-ii73.
10. Stanton-Hicks M. Complex regional pain syndrome. Anesthesiol Clin North America. 2003;21:733-744.
11. Bruehl S. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology. 2010;113:713-725.
12. Bruehl S, Harden RN, Galer BS, et al. External validation of IASP diagnostic criteria for complex regional pain syndrome and proposed research diagnostic criteria. Pain. 1999;81:147-154.
13. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191-197.
14. Beck AT, Ward CH, Mendelson MM, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
15. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-263.
16. Woolley SB, Cardoni AA, Goethe JW. Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies. Pharmacotherapy. 2009;29:1408-1416.
17. Oaklander AL. Evidence-based pharmacotherapy for CRPS and related conditions. In: CRPS Current Diagnosis and Therapy. Wilson PR, Stanton-Hicks M, Norman HR, eds. IASP Press; Seattle, WA. 2005:3-7.